| Literature DB >> 34465524 |
Janelle Patel, Nikki Christofferson, Kellie J Goodlet.
Abstract
BACKGROUND: Racial and ethnic minority groups are disproportionally represented among U.S. coronavirus disease (COVID-19) cases, owing to long-standing systemic inequities in the social determinants of health. Among Hispanic populations, a lack of access to testing sites has resulted in delayed time to diagnosis, risking increased spread within high-risk communities. The accessibility and expertise of community pharmacists support expanded pharmacist roles in public health and pandemic response, including point-of-care (POC) diagnostic testing.Entities:
Mesh:
Year: 2021 PMID: 34465524 PMCID: PMC8373847 DOI: 10.1016/j.japh.2021.08.015
Source DB: PubMed Journal: J Am Pharm Assoc (2003) ISSN: 1086-5802
Figure 1Percent positive COVID-19 diagnostic tests for Maricopa County and El Mirage testing center (May 1, 2020-September 1, 2020). Maricopa County data are per the Arizona Department of Health Services. Abbreviation used: COVID-19, coronavirus disease.
Demographics of patients without an appointment receiving COVID-19 testing from May 1, 2020 to June 14, 2020
| Characteristic | Surveyed patients (n = 622) | All patients (n = 2200) | |
|---|---|---|---|
| Age, y, mean (SD) | 42 (16.6) | 42 (16.1) | 0.192 |
| Female sex, n (%) | 319 (51.3) | 1164 (52.9) | 0.474 |
| Race/Ethnicity, n (%) | |||
| Hispanic | 398 (64.0) | 1373 (62.4) | 0.472 |
| White, non-Hispanic | 159 (25.6) | 572 (26.0) | 0.826 |
| Black or African American | 30 (4.8) | 129 (5.9) | 0.320 |
| Other | 35 (5.6) | 126 (5.7) | 0.924 |
| Positive COVID-19 test result, n (%) | 108 (17.4) | 350 (15.9) | 0.385 |
Abbreviation used: COVID-19, coronavirus disease.
Responses to patient perception survey of pharmacist-guided point-of-care COVID-19 testing and counseling (n = 622)
| Parameter | Response, n (%) | ||||
|---|---|---|---|---|---|
| Survey question | Strongly agree | Agree | Disagree | Strongly disagree | Declined to answer |
| Q1. I felt comfortable going to a community pharmacy to receive testing for COVID-19 infection. | 399 (64.2) | 219 (35.2) | 4 (0.6) | 0 | 0 |
| Q2. Having a testing center at a community pharmacy improved my access to health care services. | 385 (61.9) | 222 (35.7) | 13 (2.1) | 2 (0.3) | 0 |
| Q3. After my conversation with the pharmacist, I felt more knowledgeable about managing coronavirus signs and symptoms. | 288 (46.3) | 272 (43.7) | 55 (8.8) | 7 (1.1) | 0 |
| Q4. After my conversation with the pharmacist, I felt more knowledgeable about knowing when to seek medical attention for potential COVID-19 symptoms. | 289 (46.5) | 259 (41.6) | 67 (10.8) | 7 (1.1) | 0 |
| Q5. My test results were reported to me in a timely manner. | 412 (66.2) | 194 (31.2) | 10 (1.6) | 5 (0.8) | 1 (0.2) |
| Q6. Pharmacist-provided testing services benefit my community. | 385 (61.9) | 226 (36.3) | 8 (1.3) | 0 | 2 (0.3) |
| Q7. Overall, I am satisfied with the testing services I received. | 420 (67.5) | 197 (31.7) | 3 (0.4) | 2 (0.3) | 0 |
| Q8. I would be willing to receive a pharmacist-provided test for COVID-19 infection at a community pharmacy again. | 406 (65.3) | 203 (32.6) | 7 (1.1) | 0 | 6 (1.0) |
Abbreviations used: COVID-19, coronavirus disease; Q, question.
Subgroup comparisons among surveyed patients receiving pharmacist-guided point-of-care COVID-19 testing and counseling
| Parameter | All surveyed patients, n = 622 | COVID(+) n = 108 (17.4) | Age ≥ 65 y n = 66 (10.6) | Female n = 319 (51.2) | Hispanic n = 398 (64.0) |
|---|---|---|---|---|---|
| COVID(+) | 108 (17.4) | 108 (100) | 4 (6.1) | 63 (19.7) | 91 (22.9) |
| Q1. I felt comfortable going to a community pharmacy to receive testing for COVID-19 infection. – SA/A | 618 (99.4) | 107 (99.1) | 65 (98.5) | 317 (99.4) | 397 (99.7) |
| Q2. Having a testing center at a community pharmacy improved my access to health care services. – SA/A | 607 (97.6) | 105 (97.2) | 63 (95.5) | 310 (97.2) | 388 (97.5) |
| Q3. After my conversation with the pharmacist, I felt more knowledgeable about managing coronavirus signs and symptoms. – SA/A | 560 (90.0) | 100 (92.6) | 54 (81.8) | 283 (88.7) | 375 (94.2) |
| Q4. After my conversation with the pharmacist, I felt more knowledgeable about knowing when to seek medical attention for potential COVID-19 symptoms. – SA/A | 548 (88.1) | 100 (92.6) | 51 (77.3) | 278 (87.1) | 368 (92.5) |
| Q5. My test results were reported to me in a timely manner. – SA/A | 606 (97.4) | 104 (96.3) | 62 (93.9) | 310 (97.2) | 388 (97.5) |
| Q6. Pharmacist-provided testing services benefit my community. – SA/A | 611 (98.2) | 108 (100) | 63 (95.5) | 311 (97.5) | 393 (98.7) |
| Q7. Overall, I am satisfied with the testing services I received. – SA/A | 617 (99.2) | 107 (99.1) | 64 (97.0) | 316 (99.1) | 396 (99.5) |
| Q8. I would be willing to receive a pharmacist-provided test for COVID-19 infection at a community pharmacy again. – SA/A | 609 (97.9) | 103 (95.4) | 64 (97.0) | 311 (97.5) | 391 (98.2) |
Abbreviations used: A, agree; COVID-19, coronavirus disease; Q, question; SA, strongly agree.
Note: Values are given as n (%).
Statistically significant difference (P < 0.05) compared with all surveyed patients.